These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 25568)

  • 1. The significance of beta1-beta2-selectivity and intrinsic sympathomimetic activity in beta-blockers, with particular reference to antihypertensive treatment.
    Imhof P
    Adv Clin Pharmacol; 1976; 11():26-32. PubMed ID: 25568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ; Schalekamp MA
    Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mode of action of beta-adrenergic blocking drugs in hypertension.
    Prichard BN; Owens CW
    Clin Physiol Biochem; 1990; 8 Suppl 2():1-10. PubMed ID: 1982756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-blockers in hypertension.
    Hansson L
    J Hypertens Suppl; 1987 Aug; 5(3):S61-7. PubMed ID: 2889813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antihypertensive drugs on lipid metabolism.
    Leren P
    Clin Ther; 1987; 9(3):326-32. PubMed ID: 2886221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-adrenergic blocking agents in the treatment of hypertension. Choices based on pharmacological properties and patient characteristics.
    Wallin JD; Shah SV
    Arch Intern Med; 1987 Apr; 147(4):654-9. PubMed ID: 2881524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ; Anderson S
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term blood pressure control with pindolol given once daily.
    Frithz G; Danielson M; Henningsen N; Malmborg RO; Nordström-Ohrberg G; Schröder G
    Eur J Cardiol; 1978; 7(2-3):131-6. PubMed ID: 27369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the antihypertensive mechanisms of beta-adrenoceptor antagonists in relation to intrinsic sympathomimetic activity, cardioselectivity and hydrophilicity.
    Man in't Veld AJ; Schalekamp MA
    J Pharmacol; 1983; 14 Suppl 2():69-104. PubMed ID: 6138473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: relationship to changes in plasma renin activity, heart rate and sympathetic nerve function.
    Antonaccio MJ; High J; DeForrest JM; Sybertz E
    J Pharmacol Exp Ther; 1986 Jul; 238(1):378-87. PubMed ID: 2873238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are tolerability concerns a class effect of beta-blockers in treating patients with hypertension?
    Kountz DS
    Postgrad Med; 2009 Jan; 121(1):14-24. PubMed ID: 19179810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].
    Lemmer B
    Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular hypotensive and vasodilative effects of two beta-adrenergic blockers with intrinsic sympathomimetic activity.
    Hong SJ; Wu KY; Chen IJ
    Curr Eye Res; 1998 Jul; 17(7):700-7. PubMed ID: 9678415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacology of adrenergic beta receptor blockaders].
    Román O
    Rev Med Chil; 1991 May; 119(5):577-83. PubMed ID: 1688229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Which beta receptor blockers should be used in hypertension?].
    Werning C
    Fortschr Med; 1980 Feb; 98(5):157-60. PubMed ID: 6102958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J; Faülhaber HD
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical application of beta-blockers with particular reference to hypertension].
    Kocijancić M
    Srp Arh Celok Lek; 1992 Jun; 120 Suppl 4():10-6. PubMed ID: 18193806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive actions of an isomer of labetalol and other vasodilator-beta-adrenoceptor blockers.
    Baum T; Sybertz EJ
    Fed Proc; 1983 Feb; 42(2):176-81. PubMed ID: 6130003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central hemodynamics of beta-adrenoceptor blocking drugs: beta 1 selectivity versus intrinsic sympathomimetic activity.
    Svendsen TL
    J Cardiovasc Pharmacol; 1983; 5 Suppl 1():S21-5. PubMed ID: 6188916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.